SynthesisFrontiers in nutrition2026
Highlighting sarcopenia management in cancer treatments: evidence from umbrella meta-analysis.
Synthesis in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The role of sarcopenia in cancer treatment remains to be fully documented. This umbrella meta-analysis aimed to investigate the impact of sarcopenia on therapeutic outcomes across common malignancies with high incidence or mortality. Methods: We conducted an umbrella review of existing meta-analyses based on cohort studies. PubMed, Web of Science, and Embase were systematically searched from inception to October 2025. The primary endpoints were survival outcomes after surgical or first-line treatments. Supplementary meta-analyses were performed for outcomes with insufficient existing evidence. The systematic review protocol was registered in PROSPERO (CRD42022383726). Results: A total of 59 meta-analyses were included, comprising 49 from the literature search and 10 newly conducted in this study, covering 12 cancer types. In patients undergoing surgery, sarcopenia was significantly associated with shorter overall survival (HR = 1.59, 95% CI: 1.37-1.88) and disease-free survival (HR = 1.64, 95% CI: 1.39-1.93), as well as increased risks of any postoperative complications (OR = 1.48, 95% CI: 1.21-1.81) and major complications (OR = 1.51, 95% CI: 1.30-1.76). In patients receiving first-line non-surgical therapy, sarcopenia remained an independent risk factor for poorer overall survival (HR = 1.49, 95% CI: 1.39-1.61) and progression-free survival (HR = 1.39, 95% CI: 1.17-1.66). The methodological quality of included meta-analyses was generally high, while the GRADE certainty of evidence for most outcomes was rated as low or very low. Sarcopenia was also associated with inferior survival after cancer immunotherapy. Discussion: Sarcopenia is consistently associated with adverse therapeutic outcomes across multiple cancers and treatment modalities. It warrants attention in clinical management and represents a promising target for improving cancer therapeutic outcomes. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022383726.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.